Palafox, M., Gonzalez-Perez, A., Arribas, J., López Bigas, N., & Serra, V. (2022). High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. Nature Research.
Citação norma ChicagoPalafox, Marta, Abel Gonzalez-Perez, Joaquín Arribas, Núria López Bigas, y Violeta Serra. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER+ Breast Cancer. Nature Research, 2022.
Citação norma MLAPalafox, Marta, et al. High P16 Expression and Heterozygous RB1 Loss Are Biomarkers for CDK4/6 Inhibitor Resistance in ER+ Breast Cancer. Nature Research, 2022.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.